Skip to main content

Medical and radiation oncology

Section edited by Dirk Vordermark

This section focuses on clinical research that impacts on the treatment of cancer using systemic chemotherapy, targeted therapy, and radiation.

Page 1 of 24

  1. Standard treatments for small cell carcinoma of the cervix (SCCC) have not been established. In this study, we aimed to estimate the optimal treatment strategy for SCCC.

    Authors: Mariko Kawamura, Yutaro Koide, Taro Murai, Shunichi Ishihara, Yuuki Takase, Takayuki Murao, Dai Okazaki, Takahiro Yamaguchi, Kaoru Uchiyama, Yoshiyuki Itoh, Takeshi Kodaira, Yuta Shibamoto, Mika Mizuno, Fumitaka Kikkawa and Shinji Naganawa

    Citation: BMC Cancer 2021 21:1046

    Content type: Research article

    Published on:

  2. Standard therapy for human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC) is lacking. The clinical benefits with pan-HER inhibitors (afatinib, neratinib, and dacomitinib), ...

    Authors: Xinghao Ai, Zhengbo Song, Hong Jian, Zhen Zhou, Zhiwei Chen, Yongfeng Yu, Ziming Li and Shun Lu

    Citation: BMC Cancer 2021 21:1033

    Content type: Study protocol

    Published on:

  3. Radiation induced enteropathy is a common complication of radiotherapy for pelvic tumors and adversely affects patient quality of life. Probiotics are thought to restore bowel microflora to optimal levels and ...

    Authors: Yeon Joo Kim, Jesang Yu, Sung Pyo Park, Seung Hae Lee and Young Seok Kim

    Citation: BMC Cancer 2021 21:1032

    Content type: Study protocol

    Published on:

  4. Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refrac...

    Authors: Gabriel Tremblay, Patrick Daniele, Janis Breeze, Lingling Li, Jatin Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay Nooka, Dan Vogl, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Paul Richardson, Noa Biran, David Siegel…

    Citation: BMC Cancer 2021 21:993

    Content type: Research article

    Published on:

  5. Although chemotherapy for metastatic colorectal cancer (mCRC) has improved, the standard chemotherapy regimens for patients with RAS wild-type mCRC remain debated. This study aimed to compare S-1 and oxaliplat...

    Authors: Yujiro Nishizawa, Naotsugu Haraguchi, Hirotoshi Kim, Yoshihito Ide, Ken Nakata, Shu Okamura, Toshihiro Kudo, Taroh Satoh, Mamoru Uemura, Chu Matsuda, Tsunekazu Mizushima, Kohei Murata, Yuichiro Doki and Hidetoshi Eguchi

    Citation: BMC Cancer 2021 21:947

    Content type: Research article

    Published on:

  6. Proton beam therapy (PBT) is a new-emerging cancer treatment in China but its treatment costs are high and not yet covered by Chinese public medical insurance. The advanced form of PBT, intensity-modulated pro...

    Authors: Guo Li, Yun-Fei Xia, Yi-Xiang Huang, Deniz Okat, Bo Qiu, Jerome Doyen, Pierre-Yves Bondiau, Karen Benezery, Jin Gao and Chao-Nan Qian

    Citation: BMC Cancer 2021 21:944

    Content type: Research article

    Published on:

  7. Radiation therapy (RT) plays a key role in curative-intent treatment for locally advanced lung cancer. Radiation induced pulmonary toxicity can be significant for some patients and becomes a limiting factor fo...

    Authors: Azza Ahmed Khalil, Eric Hau, Val Gebski, Cai Grau, Harriet Gee, Tine Bisballe Nyeng, Katrina West, Stine Kramer, David Farlow, Marianne Knap, Ditte Sloth Møller, Lone Hoffmann and Katherina P. Farr

    Citation: BMC Cancer 2021 21:940

    Content type: Study protocol

    Published on:

  8. Doublet chemotherapy in combination with a biologic agent has been a standard of care in patients with metastatic colorectal cancer for over a decade. The evidence for a “lighter” treatment approach is limited...

    Authors: Ho Wai Derrick Siu, Niall Tebbutt, Lorraine Chantrill, Chris Karapetis, Christopher Steer, Kate Wilson, David Espinoza, Lisa Bailey, Sonia Yip, Jeff Cuff, Nick Pavlakis, Subotheni Thavaneswaran, Karen Briscoe, Ratnesh Srivastav, Jennifer Shannon, Eva Segelov…

    Citation: BMC Cancer 2021 21:932

    Content type: Study protocol

    Published on:

  9. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, has shown survival benefit in clinical trials of various malignant tumors. Nivolumab-induced pneumonitis is major immune-related adverse event ...

    Authors: Teppei Yamaguchi, Junichi Shimizu, Takaaki Hasegawa, Yoshitsugu Horio, Yoshitaka Inaba, Nobuhiro Hanai, Kei Muro and Toyoaki Hida

    Citation: BMC Cancer 2021 21:924

    Content type: Research article

    Published on:

  10. Intracranial hemangiopericytoma is a rare disease and surgery is the mainstay treatment. Although postoperative adjuvant radiotherapy is often used, there are no reports comparing different radiotherapy techni...

    Authors: Jianbiao Xiao, Lanwei Xu, Yi Ding, Wei Wang, Fen Chen, Yangshu Zhou, Fengjiao Zhang, Qiyuan Zhou, Xuehui Wu, Junpeng Li, Li Liang and Yee-Min Jen

    Citation: BMC Cancer 2021 21:915

    Content type: Research article

    Published on:

  11. Residual breast cancer after neo-adjuvant chemotherapy (NACT) predicts disease outcome and is a surrogate for survival in aggressive breast cancer (BC) subtypes. Pathological complete response (pCR) rate, howe...

    Authors: Alex De Caluwé, Laurence Buisseret, Philip Poortmans, Dirk Van Gestel, Roberto Salgado, Christos Sotiriou, Denis Larsimont, Marianne Paesmans, Ligia Craciun, Drisis Stylianos, Christophe Vandekerckhove, Fabien Reyal, Veys Isabelle, Daniel Eiger, Martine Piccart, Emanuela Romano…

    Citation: BMC Cancer 2021 21:899

    Content type: Study protocol

    Published on:

  12. Although various clinical trials and real-life studies have tried to explore the value of nab-paclitaxel mono-chemotherapy for metastatic breast cancer (MBC), the safety and efficacy of nab-paclitaxel remain u...

    Authors: Haili Lu, Siluo Zha, Wei Zhang, Qiang Wang, Daozhen Jiang, Xinyun Xu, Xiangmin Zheng, Ming Qiu and Chengxiang Shan

    Citation: BMC Cancer 2021 21:830

    Content type: Research article

    Published on:

  13. Adenoid cystic carcinoma is a rare form of head and neck cancer with a slow, but aggressive growth pattern which remains a challenge for local tumor control. Based on phase II data, radiation treatment using p...

    Authors: Kristin Lang, Sebastian Adeberg, Semi Harrabi, Thomas Held, Meinhard Kieser, Jürgen Debus and Klaus Herfarth

    Citation: BMC Cancer 2021 21:812

    Content type: Study protocol

    Published on:

  14. Cancer cachexia causes significant morbidity and mortality in advanced lung cancer patients. Clinical benefit of β-hydroxy-β-methylbutyrate, arginine, and glutamine (HMB/Arg/Gln) was assessed in newly diagnose...

    Authors: Jennifer Pascoe, Aimee Jackson, Charlotte Gaskell, Claire Gaunt, Joyce Thompson, Lucinda Billingham and Neil Steven

    Citation: BMC Cancer 2021 21:800

    Content type: Research article

    Published on:

  15. Tamoxifen (TAM) and Toremifene (TOR), two kinds of selective estrogen receptor modulators (SERMs), have equal efficacy in breast cancer patients. However, TAM has been proved to affect serum lipid profiles and...

    Authors: Dandan Song, Yingying Hu, Biyu Diao, Rongrong Miao, Baodan Zhang, Yangjun Cai, Hanqian Zeng, Yuru Zhang and Xiaoqu Hu

    Citation: BMC Cancer 2021 21:798

    Content type: Research article

    Published on:

  16. The incidence of anal squamous cell carcinoma has been increasing, particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs, such as protease inhibitors, commonly used in the...

    Authors: Alison K. Yoder, David S. Lakomy, Yongquan Dong, Suchismita Raychaudhury, Kathryn Royse, Christine Hartman, Peter Richardson, Donna L. White, Jennifer R. Kramer, Lilie L. Lin and Elizabeth Chiao

    Citation: BMC Cancer 2021 21:776

    Content type: Research article

    Published on:

  17. Immunotherapy is revolutionising the treatment of patients diagnosed with melanoma and other cancers. The first immune checkpoint inhibitor, ipilimumab (targeting cytotoxic T-lymphocyte-associated antigen 4 (C...

    Authors: Oliver Coen, Pippa Corrie, Helen Marshall, Ruth Plummer, Christian Ottensmeier, Jane Hook, Sue Bell, Gurdeep S. Sagoo, David Meads, Janine Bestall, Galina Velikova, Ferdia A. Gallagher, Alexandra Smith, Helen Howard, Ellen Mason, Eszter Katona…

    Citation: BMC Cancer 2021 21:761

    Content type: Study protocol

    Published on:

  18. Advanced stage marginal zone lymphoma (MZL) is an incurable indolent B-cell lymphoma, for which a wide variety of treatments ranging from single agent rituximab to more dose intense immunochemotherapy exists. ...

    Authors: Alexander Grunenberg, Lisa M. Kaiser, Stephanie Woelfle, Birgit Schmelzle, Andreas Viardot, Peter Möller, Thomas F. E. Barth, Rainer Muche, Jens Dreyhaupt, Markus Raderer, Barbara Kiesewetter and Christian Buske

    Citation: BMC Cancer 2021 21:749

    Content type: Study protocol

    Published on:

  19. Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK+ non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second...

    Authors: Petros Christopoulos, Farastuk Bozorgmehr, Lena Brückner, Inn Chung, Johannes Krisam, Marc A. Schneider, Albrecht Stenzinger, Regina Eickhoff, Daniel W. Mueller and Michael Thomas

    Citation: BMC Cancer 2021 21:743

    Content type: Study protocol

    Published on:

  20. A primary pulmonary invasive mucinous adenocarcinoma (IMA) is a rare subtype of invasive adenocarcinoma of the lung. The prognosis of advanced IMA depending on chemotherapy regimen has not been fully investiga...

    Authors: Yoon Jung Jang, Dong-gon Hyun, Chang-Min Choi, Dae Ho Lee, Sang-We Kim, Shinkyo Yoon, Woo Sung Kim, Wonjun Ji and Jae Cheol Lee

    Citation: BMC Cancer 2021 21:731

    Content type: Research article

    Published on:

  21. An unexpected recurrence of hepatocellular carcinoma (HCC) sometimes occurs in patients with hepatitis C virus (HCV) after treatment with direct-acting antivirals (DAAs). However, the characteristics of patien...

    Authors: Takao Watanabe, Yoshio Tokumoto, Kouji Joko, Kojiro Michitaka, Norio Horiike, Yoshinori Tanaka, Fujimasa Tada, Yoshiyasu Kisaka, Seiji Nakanishi, Kazuhiko Yamauchi, Hironori Ochi, Atsushi Hiraoka, Sen Yagi, Atsushi Yukimoto, Masashi Hirooka, Masanori Abe…

    Citation: BMC Cancer 2021 21:699

    Content type: Research article

    Published on:

  22. Previous clinical trials have demonstrated the potential efficacy of rechallenge with anti- epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) for patients with RAS/BRAF V600E wild-type metastat...

    Authors: Hiromichi Nakajima, Daisuke Kotani, Hideaki Bando, Takeshi Kato, Eiji Oki, Eiji Shinozaki, Yu Sunakawa, Kentaro Yamazaki, Satoshi Yuki, Yoshiaki Nakamura, Takeharu Yamanaka, Takayuki Yoshino, Takashi Ohta, Hiroya Taniguchi and Yoshinori Kagawa

    Citation: BMC Cancer 2021 21:674

    Content type: Study protocol

    Published on:

  23. To evaluate the effectiveness and safety of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during chemoradiotherapy in patients with cervical cancer.

    Authors: Dongling Zou, Mingfang Guo and Qi Zhou

    Citation: BMC Cancer 2021 21:661

    Content type: Research article

    Published on:

  24. In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligibl...

    Authors: Stefan Knop, Maria-Victoria Mateos, Meletios A. Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ganna Usenko, Ludek Pour, Mark Cook, Sebastian Grosicki, Andre Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova…

    Citation: BMC Cancer 2021 21:659

    Content type: Research article

    Published on:

  25. Nutritional complications in patients with locally advanced head and neck cancer (LA-HNC) treated by concurrent chemoradiotherapy (CCRT) often lead to placement of a prophylactic gastrostomy (PG) tube, while i...

    Authors: Tatiana Dragan, Fréderic Duprez, André Van Gossum, Akos Gulyban, Sylvie Beauvois, Antoine Digonnet, Yassine Lalami and Dirk Van Gestel

    Citation: BMC Cancer 2021 21:656

    Content type: Research article

    Published on:

  26. The prognosis of patients with small cell lung cancer (SCLC) is poor, most of them are in the extensive stage at the time of diagnosis, and are prone to brain metastasis. In this study, we established a nomogr...

    Authors: Qinge Shan, Jianxiang Shi, Xiaohui Wang, Jun Guo, Xiao Han, Zhehai Wang and Haiyong Wang

    Citation: BMC Cancer 2021 21:640

    Content type: Research article

    Published on:

  27. Although the National Comprehensive Cancer Network (NCCN) Guidelines recommend CCRT+AC and IC + CCRT as level 2A evidence for treatment of the locoregionally advanced NPC (II-IVa), IC + CCRT+AC could also be a...

    Authors: Wei Liu, Bolong Yu, Yunfan Luo, Junzheng Li, Xiaofei Yuan, Shuting Wu, Bijun Liang, Zehong Lv, Yanfei Li, Xinyu Peng, Juan Lu, Xiaohong Peng and Xiong Liu

    Citation: BMC Cancer 2021 21:639

    Content type: Research article

    Published on:

  28. Radiation-induced pneumonitis (RP) is a non-negligible and sometimes life-threatening complication among patients with thoracic radiation. We initially aimed to ascertain the predictive value of acute radiatio...

    Authors: Wenjie Tang, Xiaolin Li, Haining Yu, Xiaoyang Yin, Bing Zou, Tingting Zhang, Jinlong Chen, Xindong Sun, Naifu Liu, Jinming Yu and Peng Xie

    Citation: BMC Cancer 2021 21:585

    Content type: Research article

    Published on:

  29. Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of se...

    Authors: Young Mi Hong, K. T. Yoon and Mong Cho

    Citation: BMC Cancer 2021 21:569

    Content type: Research article

    Published on:

  30. Significant progress has been made in the treatment outcomes of mantle cell lymphoma (MCL) since the introduction of cytarabine and rituximab in modern regimens. However, older patients may not readily tolerat...

    Authors: Xinyi Yang, Lay Poh Khoo, Esther Wei Yin Chang, Valerie Shiwen Yang, Eileen Poon, Nagavalli Somasundaram, Mohamad Farid, Tiffany Pooi Ling Tang, Miriam Tao, Soon Thye Lim and Jason Yongsheng Chan

    Citation: BMC Cancer 2021 21:566

    Content type: Research article

    Published on:

  31. The chemotherapy triplet FOLFOXIRI combined to the anti-VEGF antibody bevacizumab is an option in selected patients with metastatic colorectal cancer. In this setting, RAS-mutated metastatic colorectal cancer ...

    Authors: Antoine Adenis, Thibault Mazard, Julien Fraisse, Patrick Chalbos, Brice Pastor, Ludovic Evesque, Francois Ghiringhelli, Caroline Mollevi, Stéphanie Delaine and Marc Ychou

    Citation: BMC Cancer 2021 21:564

    Content type: Study protocol

    Published on:

  32. The platelet-to-lymphocyte ratio (PLR) and C-reactive protein (CRP) level are markers that have been reported to predict the histological type of various tumors, and here, we evaluated their utility in predict...

    Authors: Rui Chen, Liguang Wang, Qi Zhao, Zhen Li, Man Chen, Guodong Lian and Junyong Zhang

    Citation: BMC Cancer 2021 21:556

    Content type: Research article

    Published on:

  33. Stereotactic body radiotherapy (SBRT) is becoming increasingly used in treating localized prostate cancer (PCa), with evidence showing similar toxicity and efficacy profiles when compared with longer courses o...

    Authors: Ting Martin Ma, James M. Lamb, Maria Casado, Xiaoyan Wang, T. Vincent Basehart, Yingli Yang, Daniel Low, Ke Sheng, Nzhde Agazaryan, Nicholas G. Nickols, Minsong Cao, Michael L. Steinberg and Amar U. Kishan

    Citation: BMC Cancer 2021 21:538

    Content type: Study protocol

    Published on:

  34. FOLFIRINOX (FFX) and Gemcitabine plus nab-paclitaxel (GnP) have been recommended as the first-line chemotherapy for metastatic pancreatic cancer (mPC). However, the evidence is lacking comparing not only two r...

    Authors: Jung Won Chun, Sang Hyub Lee, Joo Seong Kim, Namyoung Park, Gunn Huh, In Rae Cho, Woo Hyun Paik, Ji Kon Ryu and Yong-Tae Kim

    Citation: BMC Cancer 2021 21:537

    Content type: Research article

    Published on:

  35. We reported previously that rectal cancer patients given curative-intent chemotherapy, radiation, and surgery for non-metastatic disease had enhanced risk of metastatic progression and death if circulating lev...

    Authors: Hanna Abrahamsson, Sebastian Meltzer, Vidar Nyløkken Hagen, Christin Johansen, Paula A. Bousquet, Kathrine Røe Redalen and Anne Hansen Ree

    Citation: BMC Cancer 2021 21:535

    Content type: Research article

    Published on:

  36. Oxaliplatin-based therapy with FOLFOX-4 or CAPOX administered over 6 months remains the standard adjuvant treatment for stage III colon cancer (CC) patients. However, many patients experience dose reduction or...

    Authors: Jolanta Żok, Michał Bieńkowski, Barbara Radecka, Jan Korniluk, Krzysztof Adamowicz and Renata Duchnowska

    Citation: BMC Cancer 2021 21:529

    Content type: Research article

    Published on:

  37. The treatment landscape for advanced non-small cell lung cancer (aNSCLC) has evolved rapidly since immuno-oncology (IO) therapies were introduced. This study used recent data to assess real-world treatment pat...

    Authors: Jason Lester, Carles Escriu, Sarah Khan, Emma Hudson, Talal Mansy, Andrew Conn, Samuel Chan, Ceri Powell, Juliet Brock, John Conibear, Lauren Nelless, Vaneet Nayar, Xiaohui Zhuo, Adeline Durand, Amerah Amin, Peter Martin…

    Citation: BMC Cancer 2021 21:515

    Content type: Research article

    Published on:

  38. While the introduction of checkpoint inhibitors (CPIs) as standard of care treatment for various tumor types has led to considerable improvements in clinical outcome, the majority of patients still fail to res...

    Authors: Mathieu Spaas, Nora Sundahl, Eva Hulstaert, Vibeke Kruse, Sylvie Rottey, Daan De Maeseneer, Veerle Surmont, Annabel Meireson, Lieve Brochez, Dries Reynders, Els Goetghebeur, Robbe Van den Begin, Dirk Van Gestel, Vincent Renard, Piet Dirix, Pieter Mestdagh…

    Citation: BMC Cancer 2021 21:514

    Content type: Study protocol

    Published on:

  39. Concurrent chemo-radiotherapy remains the standard treatment in unresectable stage III non-small-cell lung cancer (NSCLC) patients. Several studies have shown a potential value of concurrent epidermal growth f...

    Authors: Lucheng ZHU, Changlin Zou, Zhanchun Zhang, Jianfang Wang, Li Yang, Chuangzhou Rao, Zhiping Yang, Jiafeng Liang, Bing Xia and M. A. Shenglin

    Citation: BMC Cancer 2021 21:511

    Content type: Study protocol

    Published on:

  40. Patients with myelodysplastic syndrome (MDS) require chronic red blood cell (RBC) transfusion due to anemia. Multiple RBC transfusions cause secondary iron overload and subsequent excessive generation of react...

    Authors: Lap Shu Alan Chan, Lilly ChunHong Gu and Richard A. Wells

    Citation: BMC Cancer 2021 21:509

    Content type: Research article

    Published on:

  41. Chimeric antigen-receptor T-cell and bispecific antibody therapies will likely necessitate a reconsideration of the role of autologous stem-cell transplantation (ASCT) in lymphoma. Patients who are likely to p...

    Authors: Kristina Noring, Mattias Carlsten, Kristina Sonnevi and Björn Engelbrekt Wahlin

    Citation: BMC Cancer 2021 21:500

    Content type: Research article

    Published on:

  42. A prognostic benefit of additive chemotherapy in patients following resection of metachronous colorectal liver metastases (CRLM) remains controversial. Therefore, the goal of this retrospective study was to in...

    Authors: Matthias Kelm, Julia Schollbach, Friedrich Anger, Armin Wiegering, Ingo Klein, Christoph-Thomas Germer, Nicolas Schlegel, Volker Kunzmann and Stefan Löb

    Citation: BMC Cancer 2021 21:490

    Content type: Research article

    Published on:

  43. This retrospective study aimed to evaluate the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with stereotactic body radiation therapy (SBRT) and to elucidate potential m...

    Authors: Xia Wang, Zhimin Zeng, Jing Cai, Peng Xu, Pingan Liang, Yuxi Luo and Anwen Liu

    Citation: BMC Cancer 2021 21:482

    Content type: Research article

    Published on:

  44. The initial therapeutic strategy for hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer is based on the first metastatic site; however, little evidence is available regarding the influence of...

    Authors: Jun Yamamura, Shunji Kamigaki, Junya Fujita, Hiroki Osato, Hironobu Manabe, Yumiko Tanaka, Wataru Shinzaki, Yukihiko Hashimoto and Yoshifumi Komoike

    Citation: BMC Cancer 2021 21:476

    Content type: Research article

    Published on:

  45. The objective of this study was to compare the efficacy and side effects of a single dose (Pegfilgrastim or PDL) or repeated six daily injections (Filgrastim or PDG) during chemotherapy courses in breast cance...

    Authors: Safa Najafi, Maryam Ansari, Vahid Kaveh and Shahpar Haghighat

    Citation: BMC Cancer 2021 21:454

    Content type: Research article

    Published on:

  46. Radiotherapy, along with laser surgery, is considered a standard treatment option for patients with early glottic squamous cell cancer (SCC). Historically, patients have received complete larynx radiotherapy (...

    Authors: Houda Bahig, David I. Rosenthal, Félix-Phuc Nguyen-Tan, David C. Fuller, Ying Yuan, Katherine A. Hutcheson, Apostolos Christopoulos, Anthony C. Nichols, Kevin Fung, Olivier Ballivy, Edith Filion, Sweet Ping Ng, Louise Lambert, Jennifer Dorth, Kenneth S. Hu and David Palma

    Citation: BMC Cancer 2021 21:446

    Content type: Study protocol

    Published on:

  47. To explore the feasibility of adjuvant surgery following concurrent chemoradiation therapy (CCRT) in stage IIB–IIIB (according to FIGO staging of 2009) cervical cancer and analyze risk factors of recurrence af...

    Authors: Yong Li, Zhiying Chen, Xiang Wang, Xiumei Li, Jie Zhou and Yongchun Zhang

    Citation: BMC Cancer 2021 21:442

    Content type: Research article

    Published on:

  48. Treatment beyond progression with immunotherapy may be appropriate in selected patients based on the potential for late responses. The aim of this systematic review was to explore the impact of treatment beyon...

    Authors: Francesco Spagnolo, Andrea Boutros, Federica Cecchi, Elena Croce, Enrica Teresa Tanda and Paola Queirolo

    Citation: BMC Cancer 2021 21:425

    Content type: Research article

    Published on: